实验性药物etavopivat可能减少疼痛,增加血红蛋白在状细胞疾病,研究表明. Experimental drug etavopivat may reduce pain and increase hemoglobin in sickle cell disease, study suggests.

一项新的研究表明,Etavopivat是一种实验性药物,可以减少镰状细胞疾病患者的痛苦。 A new study shows that etavopivat, an experimental drug, may reduce painful episodes in people with sickle cell disease. 52周的试验结果表明,与安慰剂相比,该药物可以降低疼痛危机的频率,并增加血红蛋白水平。 The 52-week trial results indicate the drug could lower the frequency of pain crises and increase hemoglobin levels compared to a placebo. 在美国血病学学会会议上提出的这些调查结果表明, " etavopivat " 是一种有希望的治疗方法,但还需要进一步进行第三阶段试验,以证实这些结果。 These findings, presented at the American Society of Hematology meeting, suggest etavopivat could be a promising treatment, though further phase 3 trials are needed to confirm these results.